Skip to main content
Top
Published in: Osteoporosis International 6/2004

01-06-2004 | Original Article

An evaluation of the United Kingdom National Osteoporosis Society position statement on the use of peripheral dual-energy X-ray absorptiometry

Authors: Rajesh Patel, Glen M. Blake, Ignac Fogelman

Published in: Osteoporosis International | Issue 6/2004

Login to get access

Abstract

A recent position statement issued by the UK National Osteoporosis Society recommends a triage approach to the use of peripheral dual-energy X-ray absorptiometry (pDXA) devices. Patients with a forearm T-score greater than –1 or less than –2.5 are regarded as normal or osteoporotic, respectively, while those with a T-score between –1 and –2.5 are sent for further assessment with spine and hip DXA. We have evaluated the NOS pDXA algorithm by comparing it with the alternative strategies of relying on forearm BMD alone, or performing spine and hip DXA in every patient. The evaluation was carried out using a mathematical model, and the predictions were compared with in vivo data obtained in patients referred for investigation by their general practitioner. In the model the population distribution of spine, hip, and forearm BMD was described by a trivariant Gaussian function. Relative risks of fracture were taken from a meta-analysis. The three strategies were compared using receiver operating characteristic (ROC) curves in which the percentage of future fracture cases identified was plotted against the percentage of the whole population found to have osteoporosis. ROC curves plotted for the discrimination of hip, vertebral, and Colles fracture risk and the risk of a fracture at any skeletal site were similar for all three strategies, with the curves for the NOS pDXA algorithm nearly identical to those for spine and hip DXA. For the case of hip fracture, vertebral fracture, or a fracture at any site, forearm BMD was slightly inferior to the NOS algorithm, but the reverse was true for Colles fracture. The small difference between the ROC curves suggests that forearm BMD used alone can reproduce clinical decision-making with the NOS pDXA algorithm provided that a T-score threshold of T=–2.1 is used for the diagnosis of osteoporosis, instead of the conventional figure of T=–2.5. Results from the in vivo study were in good agreement with the predictions of the model, although some differences were observed that were explained by inaccuracies in the forearm reference data. We conclude that use of forearm BMD alone with a modified T-score threshold of –2.1 would save the need for spine and hip DXA scans and identify only slightly fewer fracture cases for treatment.
Literature
1.
go back to reference Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMed Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMed
2.
go back to reference Ray NF, Chan JK, Thamer M, Melton LJ (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35PubMed Ray NF, Chan JK, Thamer M, Melton LJ (1997) Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 12:24–35PubMed
3.
go back to reference Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, on behalf of the European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int 7:390–406PubMed Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, on behalf of the European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int 7:390–406PubMed
4.
go back to reference Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMed Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541PubMed
5.
go back to reference Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMed Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMed
6.
go back to reference Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMed Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645PubMed
7.
go back to reference Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352PubMed Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352PubMed
8.
go back to reference Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91PubMed Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91PubMed
9.
go back to reference Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124PubMed Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85:4118–4124PubMed
10.
go back to reference McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340CrossRefPubMed McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340CrossRefPubMed
11.
go back to reference Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344:1434–1441PubMed Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344:1434–1441PubMed
12.
go back to reference Delmas PD, Ensrud KE, Adachi JD et al (2001) Efficacy of raloxifene on vertebral fracture risk in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617CrossRef Delmas PD, Ensrud KE, Adachi JD et al (2001) Efficacy of raloxifene on vertebral fracture risk in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617CrossRef
13.
go back to reference Royal College of Physicians (2000) Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. RCP, London Royal College of Physicians (2000) Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. RCP, London
14.
go back to reference US Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Arch Intern Med 137:526–528 US Preventive Services Task Force (2002) Screening for osteoporosis in postmenopausal women: recommendations and rationale. Arch Intern Med 137:526–528
15.
go back to reference Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMed Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMed
16.
go back to reference WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, No. 843. World Health Organization, Geneva WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series, No. 843. World Health Organization, Geneva
17.
go back to reference National Osteoporosis Society (2002) Position statement on the reporting of dual energy X-ray absorptiometry (DXA) bone mineral density scans. NOS, Bath, England National Osteoporosis Society (2002) Position statement on the reporting of dual energy X-ray absorptiometry (DXA) bone mineral density scans. NOS, Bath, England
18.
go back to reference Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMed Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMed
19.
go back to reference Miller PD, Siris ES, Barrett-Connor E et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17:2222–2230PubMed Miller PD, Siris ES, Barrett-Connor E et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17:2222–2230PubMed
20.
go back to reference Augat P, Fuerst T, Genant HK (1998) Quantitative bone mineral assessment at the forearm: a review. Osteoporos Int 8:299–310CrossRefPubMed Augat P, Fuerst T, Genant HK (1998) Quantitative bone mineral assessment at the forearm: a review. Osteoporos Int 8:299–310CrossRefPubMed
21.
go back to reference Blake GM, Wahner HW, Fogelman I (1999) The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. Martin Dunitz, London, pp 89–105 Blake GM, Wahner HW, Fogelman I (1999) The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. Martin Dunitz, London, pp 89–105
22.
go back to reference National Osteoporosis Society (2001) Position statement on the use of peripheral X-ray absorptiometry in the management of osteoporosis. NOS, Bath, England National Osteoporosis Society (2001) Position statement on the use of peripheral X-ray absorptiometry in the management of osteoporosis. NOS, Bath, England
23.
go back to reference Lu Y, Genant HK, Shepherd J et al (2001) Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 16:901–910PubMed Lu Y, Genant HK, Shepherd J et al (2001) Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 16:901–910PubMed
24.
go back to reference Trumpler RJ, Weaver HF (1962) Statistical astronomy. Dover, New York, pp 42–68 Trumpler RJ, Weaver HF (1962) Statistical astronomy. Dover, New York, pp 42–68
25.
go back to reference Blake GM, Patel R, Knapp KM, Fogelman I (2003) Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res 18:1955–1963PubMed Blake GM, Patel R, Knapp KM, Fogelman I (2003) Does the combination of two BMD measurements improve fracture discrimination? J Bone Miner Res 18:1955–1963PubMed
26.
go back to reference Blake GM, Fogelman I (2001) Peripheral or Central Densitometry: does it matter which we use? J Clin Densitom 4:83–96 Blake GM, Fogelman I (2001) Peripheral or Central Densitometry: does it matter which we use? J Clin Densitom 4:83–96
27.
go back to reference Kelly TL (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5[Suppl 2]:S249 Kelly TL (1990) Bone mineral density reference databases for American men and women. J Bone Miner Res 5[Suppl 2]:S249
28.
go back to reference Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489CrossRefPubMed Looker AC, Wahner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489CrossRefPubMed
29.
go back to reference Cooper C, Atkinson EJ, Jacobsen SJ et al (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiology 137:1001–1005 Cooper C, Atkinson EJ, Jacobsen SJ et al (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiology 137:1001–1005
30.
go back to reference Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMed Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMed
31.
go back to reference Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617PubMed Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617PubMed
32.
go back to reference Torgerson DJ, Dolan P (2000) The cost of treating osteoporotic fractures in the United Kingdom female population (letter to the editor). Osteoporos Int 11:511–512 Torgerson DJ, Dolan P (2000) The cost of treating osteoporotic fractures in the United Kingdom female population (letter to the editor). Osteoporos Int 11:511–512
33.
go back to reference Grampp S, Genant HK, Mathur A et al (1997) Comparisons of non-invasive bone mineral measurements in assessing age-related bone loss, fracture discrimination and diagnostic classification. J Bone Miner Res 12:697–711PubMed Grampp S, Genant HK, Mathur A et al (1997) Comparisons of non-invasive bone mineral measurements in assessing age-related bone loss, fracture discrimination and diagnostic classification. J Bone Miner Res 12:697–711PubMed
34.
go back to reference Faulkner KG, VonStetton E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343–350PubMed Faulkner KG, VonStetton E, Miller P (1999) Discordance in patient classification using T-scores. J Clin Densitom 2:343–350PubMed
35.
go back to reference Miller PD (2000) Controversies in bone mineral density diagnostic classifications. Calcif Tissue Int 66:317–319CrossRefPubMed Miller PD (2000) Controversies in bone mineral density diagnostic classifications. Calcif Tissue Int 66:317–319CrossRefPubMed
36.
go back to reference Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMed Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMed
37.
go back to reference Bouxsein ML, Parker RA, Greenspan SL (1999) Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporos Int 10:505–509CrossRefPubMed Bouxsein ML, Parker RA, Greenspan SL (1999) Forearm bone mineral densitometry cannot be used to monitor response to alendronate therapy in postmenopausal women. Osteoporos Int 10:505–509CrossRefPubMed
38.
go back to reference Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrin Met 87(10):4528–4535CrossRef Body JJ, Gaich GA, Scheele WH et al (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrin Met 87(10):4528–4535CrossRef
39.
go back to reference National Osteoporosis Society (2001) Position statement on the use of quantitative ultrasound in the management of osteoporosis. NOS, Bath, England National Osteoporosis Society (2001) Position statement on the use of quantitative ultrasound in the management of osteoporosis. NOS, Bath, England
40.
go back to reference Blake GM, Fogelman I (1997) Interpretation of bone densitometry studies. Semin Nucl Med 27:248–260PubMed Blake GM, Fogelman I (1997) Interpretation of bone densitometry studies. Semin Nucl Med 27:248–260PubMed
Metadata
Title
An evaluation of the United Kingdom National Osteoporosis Society position statement on the use of peripheral dual-energy X-ray absorptiometry
Authors
Rajesh Patel
Glen M. Blake
Ignac Fogelman
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 6/2004
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-003-1565-2

Other articles of this Issue 6/2004

Osteoporosis International 6/2004 Go to the issue